Jasper Therapeutics Inc. (NASDAQ:JSPR)’s traded shares stood at 4.12 million during the last session. At the close of trading, the stock’s price was $1.87, to imply an increase of 3.89% or $0.07 in intraday trading. The JSPR share’s 52-week high remains $4.62, putting it -147.06% down since that peak but still an impressive 79.14% since price per share fell to its 52-week low of $0.39. The company has a valuation of $203.53M, with an average of 1.19 million shares in intraday trading volume over the past 10 days and average of 3.97 million shares over the past 3 months.
Analysts have given a consensus recommendation of a Buy for Jasper Therapeutics Inc. (JSPR), translating to a mean rating of 1.60. Of 5 analyst(s) looking at the stock, 0 analyst(s) give JSPR a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 5 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.36.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
Jasper Therapeutics Inc. (NASDAQ:JSPR) trade information
After registering a 3.89% upside in the last session, Jasper Therapeutics Inc. (JSPR) has traded red over the past five days. The stock hit a weekly high of 1.9800 this Friday, 03/17/23, jumping 3.89% in its intraday price action. The 5-day price performance for the stock is 8.09%, and 7.16% over 30 days. With these gigs, the year-to-date price performance is 287.24%. Short interest in Jasper Therapeutics Inc. (NASDAQ:JSPR) saw shorts transact 1.34 million shares and set a 0.14 days time to cover.
Analysts on Wall Street suggest a consensus price target of $6.21, implying an increase of 69.89% to the stock’s current value. The extremes give us $4.00 and $8.00 for target low and target high price respectively. As such, JSPR has been trading -327.81% off suggested target high and -113.9% from its likely low.
Jasper Therapeutics Inc. (JSPR) estimates and forecasts
Looking at statistics comparing Jasper Therapeutics Inc. share performance against respective industry, we note that the company has outperformed competitors. Jasper Therapeutics Inc. (JSPR) shares are 43.85% up over the last 6 months, with its year-to-date growth rate higher than industry average at 40.78% against 9.60%. Revenue is forecast to grow 54.40% this quarter before falling -183.30% for the next one.
Jasper Therapeutics Inc. has its next earnings report out between May 10 and May 15. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Jasper Therapeutics Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Jasper Therapeutics Inc. (NASDAQ:JSPR)’s Major holders
Jasper Therapeutics Inc. insiders hold 11.30% of total outstanding shares, with institutional holders owning 33.17% of the shares at 37.40% float percentage. In total, 33.17% institutions holds shares in the company, led by Qiming U.s. Ventures Management, Llc. As of Dec 30, 2022, the company held over 5.85 million shares (or 15.79% of shares), all amounting to roughly $2.83 million.
The next major institution holding the largest number of shares is Abingworth, LLP with 5.63 million shares, or about 15.18% of shares outstanding. As of the market price on Sep 29, 2022, these shares were worth $4.44 million.
We also have Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Jasper Therapeutics Inc. (JSPR) shares. Going by data provided on Sep 29, 2022, Vanguard Total Stock Market Index Fund holds roughly 0.33 million shares. This is just over 0.88% of the total shares, with a market valuation of $0.26 million. Data from the same date shows that the other fund manager holds a little less at 0.2 million, or 0.54% of the shares, all valued at about 0.16 million.